Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
The response includes several statements consistent with the provided COUMADIN label excerpts on bleeding risk signs/symptoms and INR-related risk/monitoring. However, it makes multiple detailed claims about acetaminophen–warfarin interaction specifics (dose/duration effects, INR rise likelihood, and product-form differences) that are not supported by the supplied label text.
Category Scores
Accurate Statements
A higher INR (e.g., INR >4.0) is associated with higher bleeding risk in people taking warfarin (COUMADIN).
Label 2.2: “An INR of greater than 4.0... is associated with a higher risk of bleeding.”
COUMADIN can cause major or fatal bleeding.
Label 5.1: “COUMADIN can cause major or fatal bleeding.”
Regular INR monitoring is required/should be performed during COUMADIN therapy.
Label 5.1 and 2.4: “Perform regular monitoring of INR in all treated patients.” and “Perform periodic INRs.”
Signs/symptoms of bleeding include bruising, nosebleeds, bleeding gums, red/tarry/black stools, red/dark brown urine, headache, and dizziness.
Label 17: “Signs and symptoms of bleeding include: ... nosebleeds, bleeding of gums... unusual bleeding or bruising, red or dark brown urine, red or tar black stools, headache, dizziness...”
Patients should notify their physician immediately if unusual bleeding or symptoms occur.
Label 17: “Notify their physician immediately if any unusual bleeding or symptoms occur.”
Warfarin dosing must be individualized to the patient’s INR response.
Label 2.1: “The dosage... must be individualized... Adjust the dose based on the patient’s INR...”
Because INR and bleeding risk can be affected by other drugs, more frequent INR monitoring should be performed when other drugs are started/stopped or dosages change.
Label 7 and 2.4: “More frequent INR monitoring... when starting or stopping other drugs... or when changing dosages of other drugs” and “Perform additional INR tests when other medications are initiated, discontinued, or taken irregularly.”
Unsupported Statements
Tylenol (acetaminophen) can raise the risk of bleeding in people taking Coumadin (warfarin).
No acetaminophen–warfarin interaction content is included in the provided COUMADIN label excerpts.
The bleeding risk with acetaminophen and warfarin is mainly increased when acetaminophen is taken in higher doses.
Dose–response specifics for acetaminophen are not provided in the supplied label text.
The bleeding risk with acetaminophen and warfarin is mainly increased when acetaminophen is taken for several days.
Time-course specifics for acetaminophen are not provided in the supplied label text.
Acetaminophen can increase warfarin’s effect.
No acetaminophen effect on warfarin is described in the provided excerpts.
Acetaminophen can lead to a higher INR in people taking warfarin.
No acetaminophen-specific INR effect is included in the provided label text.
Using more than the usual, label-recommended acetaminophen dose increases the chance of an interaction with warfarin.
The label excerpts provided do not mention acetaminophen dosing or interactions.
Repeated dosing of acetaminophen over multiple days increases the chance of an interaction with warfarin.
The label excerpts provided do not mention acetaminophen dosing duration or interactions.
Many clinicians advise staying within the lowest effective acetaminophen dose when taking warfarin.
Not supported by the provided COUMADIN label excerpts (they do not provide acetaminophen-specific counseling).
Many clinicians advise not exceeding the daily maximum acetaminophen dose on the product label when taking warfarin.
Not supported by the provided COUMADIN label excerpts.
Clinicians may advise checking an INR during the period a person takes acetaminophen for regular pain or fever control.
The label supports additional INR monitoring when other drugs are initiated/stopped or taken irregularly, but does not specifically mention acetaminophen or “regular pain or fever control.”
A single dose of acetaminophen is less likely to cause a dangerous INR rise than repeated dosing.
No acetaminophen-specific single-dose vs repeated-dose interaction information is provided.
Individuals vary in INR response to acetaminophen while taking warfarin.
No acetaminophen-specific variability information is provided.
Some people may experience unexpected INR changes after taking acetaminophen while on warfarin.
No acetaminophen-specific INR change information is provided.
The interaction is driven by the amount of acetaminophen ingested rather than whether the Tylenol product is “PM” versus regular.
No label content about Tylenol PM vs regular or acetaminophen-product-form differences is provided.
Different Tylenol products contain different amounts of acetaminophen.
Not supported by the provided COUMADIN label excerpts (and not reflected in the supplied text).
Some Tylenol products include extra ingredients (e.g., antihistamines in “PM” products).
Not supported by the provided COUMADIN label excerpts.
Other ingredients in Tylenol products can affect drowsiness or other conditions.
Not supported by the provided COUMADIN label excerpts.
Many NSAIDs increase bleeding risk with warfarin.
The provided excerpts do not list NSAIDs specifically in the interaction table text.
Acetaminophen may be used at conservative dosing under guidance for pain relief in people taking warfarin.
The provided excerpts do not include acetaminophen-specific guidance or dosing.
If a person already took acetaminophen, they should contact their anticoagulation clinic or prescribing clinician for guidance, especially if they took more than the recommended dose or plan to keep taking it.
This is not supported by the provided label excerpts (no acetaminophen-specific counseling).
After taking acetaminophen while on warfarin, a person should ask whether they should get an INR check.
General INR monitoring upon drug changes is supported, but acetaminophen-specific counseling about asking for INR checks is not in the provided text.
Contradictions
Low
AI Statement
A person should not stop or change Coumadin without medical advice because that can increase risk of clotting.
Label Reference
Not contradicted by the provided label excerpts, but this statement is not supported by the supplied text.
Important Omissions
The response does not anchor any acetaminophen–warfarin interaction claims to the provided COUMADIN label sections (e.g., Table 3) because the supplied excerpts do not include such acetaminophen-specific interaction details.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several statements are unsubstantiated by the provided COUMADIN label excerpts and introduce specific acetaminophen interaction details (dose/time/product-form) that could mislead risk assessment; however, the response does include label-consistent bleeding signs and INR monitoring principles.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Acetaminophen–warfarin interaction claims (dose/duration/INR rise and product-form distinctions) are not supported by the supplied COUMADIN label excerpts.
Suggested Improvement
Limit claims to label-supported general warfarin bleeding risk, INR thresholds (e.g., INR >4.0), and general guidance to perform additional INR monitoring when other drugs are started/stopped or taken irregularly; remove acetaminophen-specific assertions not present in the provided label text.